Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01229410 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01229410 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 24 participants.
The verdict
NCT01229410, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.
Interventions
- DRUG 400 µg Brimonidine Tartrate Implant
- DRUG 200 µg Brimonidine Tartrate Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01229410
The ClinicalTrials.gov registry entry for NCT01229410 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 400 µg Brimonidine Tartrate Implant is the first listed.
NCT01229410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01229410 about?
NCT01229410 is a clinical study titled "Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy". This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.
What is the current status of trial NCT01229410?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01229410?
The interventions under investigation include: 400 µg Brimonidine Tartrate Implant (DRUG), 200 µg Brimonidine Tartrate Implant (DRUG).
Who is sponsoring clinical trial NCT01229410?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.